small molecule

ANZUPGO

DELGOCITINIB

Loss of exclusivitySeptember 2031latest FDA-listed patent expiry

CompanyLEO PHARMA AS

Drug detail

Brand name	ANZUPGO
Active ingredient	DELGOCITINIB
Strength	2%
Dosage form	CREAM
Route	TOPICAL
Modality	Small molecule
FDA approval	July 2025
Marketing status	RX

Listed patents

Patent	Expires	Type
8609647	September 2031	substance, product

Regulatory exclusivity

Code	Expires
NCE	July 2030

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from LEO PHARMA AS